SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549-1004
FORM 8-K
CURRENT REPORT PURSUANT TO
SECTION 13 OF
THE SECURITIES EXCHANGE
ACT OF 1934
Date of Report (date of earliest event reported): October 27, 2004
Ciphergen Biosystems, Inc.
(Exact name of Registrant as specified in its charter)
|
Delaware |
000-31617 |
33-059-5156 |
|
(State or other jurisdiction of |
(Commission File Number) |
(I.R.S. Employer |
|
|
|
|
|
6611 Dumbarton Circle |
||
|
(Address of principal executive offices) |
||
|
|
|
|
|
(510) 505-2100 |
||
|
(Registrant’s telephone number, including area code) |
||
|
o |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
|
|
o |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
|
|
o |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
|
|
o |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 1.01. Entry into a Material Definitive Agreement.
On October 28, 2004 Ciphergen Biosystems, Inc. (“Ciphergen”) announced it had entered into a definitive agreement with Pall Corporation (“Pall”) to dispose of substantially all of the assets and liabilities of Ciphergen’s BioSepra process chromatography business (the “BioSepra Business”). Pursuant to that certain Asset Purchase Agreement, dated as of October 27, 2004 (the “Agreement”), by and between Pall and Ciphergen, Pall will pay Ciphergen approximately $32,000,000, net of cash and debt associated with the BioSepra Business, subject to certain other adjustments as set forth in the Agreement. The Agreement also includes certain representations, warranties and covenants, as well as closing conditions, and is expected to close within forty-five days of the date of the Agreement.
A press release was issued regarding this disposition. A copy of the press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
|
|
(a) |
Exhibits |
|
|
|
|
|
|
||
|
|
|
99.1 |
Press Release dated October 28, 2004 |
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
Ciphergen Biosystems, Inc. |
|||
|
|
(Registrant) |
|||
|
|
|
|||
|
|
|
|||
|
Date: October 28, 2004 |
By: |
|
/s/ William E. Rich |
|
|
|
William E. Rich |
|||
|
|
President and Chief Executive Officer |
|||
2
EXHIBIT INDEX
|
Exhibit |
|
Description |
|
|
99.1 |
|
Press Release dated October 28, 2004 |
|
3